Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib

Proteasome inhibitors: Dozens of molecules and still counting

(2010) Geoffroy de Bettignies et al.   BIOCHIMIE

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

(2010) Lawrence R. Dick et al.   DRUG DISCOVERY TODAY

Smurf control in bone cells

(2010) Lianping Xing et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Bone morphogenetic protein-2 down-regulates miR-206 expression by blocking its maturation process

(2009) Mari M. Sato et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

(2009) Bryan T. MacDonald et al.   DEVELOPMENTAL CELL

Bone morphogenetic protein-2 enhances Wnt/β-catenin signaling-induced osteoprotegerin expression

(2009) Mari M. Sato et al.   GENES TO CELLS

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer

(2009) Baozhi Chen et al.   Nature Chemical Biology

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology

(2008) Alan L. Schwartz et al.   Annual Review of Pharmacology and Toxicology

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

General Transcription Factor IIA-γ Increases Osteoblast-specificOsteocalcinGene Expression via Activating Transcription Factor 4 and Runt-related Transcription Factor 2

(2008) Shibing Yu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY